As Pharma Looks Beyond The Molecule For Innovation, Can VCs Take Advantage?
This article was originally published in Start Up
Big Pharma’s growing interest in innovation beyond the molecule that improves health outcomes could provide new opportunities for biotechs and their venture capital backers, but in many areas investors have approached cautiously.
You may also be interested in...
Parkinson’s disease is crowded, but Civitas’ value proposition is attractive because the unmet need remains high, the technology shows promise, the clinical trials are straightforward and relatively rapid, and the company, a spinout of Alkermes, starts with clinically validated assets and infrastructure.
The Centers for Medicare and Medicaid Services’ long awaited final rules on Accountable Care Organizations, issued on Oct. 20, include encouraging incentives for medication adherence. That’s good news for the industry, but it also throws a spotlight on the imperfect state of medication adherence methodologies.
Responding to a convergence of a changing market and shifts in technology, pharmaceutical companies are exploring ways to enhance the value of their products and find new opportunities beyond their core molecule-driven businesses.